Novel treatment options for non-Hodgkin lymphoma

0 Views

06/26/23

Graham Collins, MA, MBBS, MRCP, FRCPath, DPhil, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, discusses the findings from recent studies investigating treatment options for non-Hodgkin lymphoma. Dr Collins focuses on the POLARIX study (NCT03274492), which compares R-CHOP with polatuzumab vedotin plus R-CHP. Results indicate an increased progression-free survival (PFS) and a reduction in subsequent anti-lymphoma treatments. Dr Collins also discusses factors which may influence the future use of this treatment in diffuse large B-cell lymphoma (DLBCL). This interview took place at the 63rd American Society of Hematology Annual Meeting and Exposition, Atlanta, 2021.